Here are five things to know:
1. This patient marks the fourth patient to demonstrate AIS grade improvement with at least two months of follow-up data.
2. To meet the Objective Performance Criterion, InVivo needs to observe one more improved patient case.
3. The company plans to enroll 13 more patients to reach 20 patients at six months.
4. InVivo hopes to reach full enrollment by the end of 2016 and file for Humanitarian Device Exemption approval in 2017.
5. The INSPIRE study tests the Neuro-Spinal Scaffold for safety and neurologic recovery in patients with complete thoracic AIS A spinal cord injury.
More articles on devices:
Zimmer Biomet net sales reach $1.9B; Knee division sales up 51.6%: 8 key points
NuVasive to launch 5 new surgical solutions at AANS: 3 takeaways
ChoiceSpine celebrates its 10th year in business — 5 highlights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
